Navepegritide Clears Litigation but Enters Achondroplasia Market Carrying a 20% Royalty Burden Against an Established Rival

Ascendis and BioMarin Settle Litigation, License YUVIWEL

Ascendis Pharma A/S and BioMarin Pharmaceutical Inc. have entered into a binding term sheet for a global settlement and license agreement concerning YUVIWEL® (navepegritide). This agreement resolves all existing litigation and disputes between the companies. Under the terms, BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license for navepegritide-related products, waiving certain regulatory rights and dismissing proceedings. In return, Ascendis will dismiss its proceedings against BioMarin and pay royalties on net sales of navepegritide-related products: 20% in the U.S. and 18% in the EU, South Korea, and Brazil, from the first commercial sale through May 20, 2030. YUVIWEL was approved by the U.S. FDA in February 2026 for pediatric achondroplasia.

• The binding term sheet establishes a global settlement and license agreement, granting Ascendis Pharma a non-exclusive, worldwide, royalty-bearing license for navepegritide-related products. This allows Ascendis to continue researching, developing, manufacturing, and commercializing the product without restriction. BioMarin has also agreed to waive specific regulatory rights, dismiss all ongoing proceedings, and provide a covenant not to sue regarding the covered intellectual property, ensuring a clear path forward for Ascendis.
• As part of the agreement, Ascendis Pharma will make royalty payments to BioMarin based on net sales of navepegritide-related products. The royalty rates are set at 20% for sales in the United States and 18% for sales in the European Union, South Korea, and Brazil. These payments will commence from the first commercial sale of YUVIWEL in each respective country and will continue through May 20, 2030, representing a significant financial component of the settlement.
• YUVIWEL (navepegritide) is a prodrug of C-type natriuretic peptide (CNP) designed to counteract overactive FGFR3 signaling in achondroplasia. It received U.S. FDA approval in February 2026 for increasing linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses. Ascendis Pharma's Marketing Authorisation Application for YUVIWEL is currently under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026, indicating potential market expansion.

Addressing Achondroplasia's Unmet Needs: The YUVIWEL Context

Despite meaningful advances in targeted therapy, achondroplasia management remains constrained by a range of clinical, surgical, and pharmacological limitations that span the patient's entire lifespan.

• Vosoritide does not eliminate the need for complication surveillance. Treatment with vosoritide does not negate the necessity of actively surveilling for the potential complications of achondroplasia, which are part of its natural history. Complications including foramen magnum stenosis, hydrocephalus, obstructive and central sleep apnea, spinal stenosis, and genu varum require ongoing multidisciplinary monitoring regardless of pharmacological intervention.

• Not all patients respond to vosoritide. Not all treated children exhibit a response in linear growth, and some children and their families do not automatically desire such treatment. This variability in response and patient preference limits the universal applicability of the therapy.

• Surgical interventions carry procedure-specific risks and long-term uncertainties. Lumbar decompression in pediatric patients requires meticulous surgical planning to prevent complications such as the development of thoracolumbar kyphosis. Preserving posterior elements responsible for maintaining spinal stability is critical, and long-term follow-up remains crucial for monitoring potential kyphotic deformity. Similarly, humeral lengthening, while feasible, has historically raised concerns about neurovascular complications and functional implications.

• The pathophysiology of hydrocephalus in achondroplasia complicates treatment selection. Hydrocephalus is presumed to be "vascular" in origin and therefore communicating, which would render endoscopic third ventriculostomy (ETV) contraindicated in standard practice. The variable pressure gradients across the jugular foramen and the potential for some degree of obstructive hydrocephalus add diagnostic and therapeutic complexity.

• Long-term outcomes of vosoritide on adult height, skeletal deformities, and quality of life remain to be fully established. Ongoing studies are expected to clarify its effects on adult height, potential effects on skeletal deformities, and overall quality of life, indicating that the evidence base is still maturing.

• Adverse effects and administration burden persist with vosoritide. Injection site reactions were the most common adverse drug reaction observed in real-world use, and the therapy requires daily subcutaneous injections, which may affect long-term adherence, particularly in younger patients.

Navepegritide's Broader Pipeline Potential Beyond Achondroplasia

Beyond its approved indication in achondroplasia, navepegritide is also being investigated for hypochondroplasia. This represents an extension of the same mechanistic rationale — sustained CNP release to counteract overactive fibroblast growth factor receptor 3 signaling — into a related skeletal dysplasia.

The knowledge base does not have sufficient information on this aspect.

Unlocking Navepegritide's Potential in Achondroplasia

The recent global settlement between Ascendis Pharma and BioMarin marks a crucial turning point for the achondroplasia treatment landscape, effectively clearing the path for Ascendis's YUVIWEL (navepegritide) to reach patients without the shadow of ongoing litigation. This agreement is more than a legal resolution; it signifies the unhindered entry of a promising new therapy into a market historically dominated by supportive care.

Navepegritide, a long-acting prodrug of C-type natriuretic peptide (CNP), represents a significant advancement. Research shows it directly counteracts the overactive fibroblast growth factor receptor 3 (FGFR3) signaling that underlies achondroplasia. Clinical trials have demonstrated its ability to significantly improve annualized growth velocity and positively impact other critical skeletal outcomes, such as limb alignment, alongside improvements in physical functioning for pediatric patients. Its once-weekly subcutaneous dosing offers a convenient administration schedule, which can be a key factor for patient adherence in chronic conditions.

However, the road ahead is not without its complexities. Navepegritide enters a competitive field, with other targeted molecular therapies like vosoritide and infigratinib also showing promise in improving growth. Differentiating YUVIWEL in this evolving market will be paramount, especially given the current lack of head-to-head comparative studies. Furthermore, while short-term growth benefits are clear, the long-term impact on the multisystemic complications of achondroplasia, such as foramen magnum stenosis or sleep apnea, is still under investigation. These long-term data will be crucial for establishing its full value proposition to clinicians and payers.

Strategically, Ascendis gains a clear runway for commercialization, allowing it to fully explore the drug's potential, including its use in combination therapies. Studies indicate that combining navepegritide with agents like lonapegsomatropin can lead to even greater growth velocity, suggesting a future where synergistic approaches could become the standard of care. For BioMarin, the agreement secures a valuable royalty stream, validating its early research contributions. Yet, for Ascendis, the substantial royalty payments will necessitate careful financial management to ensure profitability and continued investment in this important therapeutic area. The coming years will reveal how YUVIWEL navigates these opportunities and challenges, ultimately shaping the future of achondroplasia management.